Dedicated rare disease unit to be headquartered in Boston Geographical presence to be enhanced with broad coverage across primary, speciality and highly specialised care Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend The acquisition will be immediately core earnings-accretive and value-enhancing, and is aligned with stated capital-allocation priorities December 12, 2020 07:48 AM Eastern Standard Time – CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.